# Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

> **NCT04136535** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 105 (estimated)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04136535
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-18
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136535, "Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04136535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*